Aktis Oncology Announces FDA Clearance of…

Ahmed Habib, MD is a board certified cardiologist and a member of the medical staff at Moberly Regional Medical Center, and on faculty at the University Hospital in Columbia. He has been practicing in Moberly since 1995. Lately, Dr. Habib has been using an innovative new device for patients who have 100 percent blocked arteries in their legs.

Plaque-piercing device relieves patients' clogged arteries.

Lakewood Ranch Medical Center is the first acute care center in the area to offer a new high-tech procedure that can take the place of bypass surgery for some patients.

Ranch cardiologist performs new surgery.

FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced FDA 510(k) clearance and immediate U.S. launch of the CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters.

FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced it has raised $30 million in Series C financing. Gilde Healthcare Partners led the financing, joined by new investors Life Sciences Partners, Hambrecht & Quist Capital Management LLC and New Science Ventures and existing investors Frazier Healthcare Ventures, JP Morgan Partners and Pappas Ventures. Rockport Venture Partners and Gold Hill Capital also participated in this round.

FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, announcedFDA 510(k)clearance of the CROSSER(TM) 14 CTO Recanalization System. The CROSSER 14 is designed to facilitate the placement of guidewires beyond CTOs in coronary arteries.